| Literature DB >> 26108440 |
Jérôme Ambroise1, Valentina Butoescu2, Annie Robert3, Bertrand Tombal4, Jean-Luc Gala5.
Abstract
BACKGROUND: Single Nucleotide Polymorphisms (SNPs) identified in Genome Wide Association Studies (GWAS) have generally moderate association with related complex diseases. Accordingly, Multilocus Genetic Risk Scores (MGRSs) have been computed in previous studies in order to assess the cumulative association of multiple SNPs. When several SNPs have to be genotyped for each patient, using successive uniplex pyrosequencing reactions increases analytical reagent expenses and Turnaround Time (TAT). While a set of several pyrosequencing primers could theoretically be used to analyze multiplex amplicons, this would generate overlapping primer-specific pyro-signals that are visually uninterpretable.Entities:
Mesh:
Year: 2015 PMID: 26108440 PMCID: PMC4630960 DOI: 10.1186/s12881-015-0186-x
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
List of selected SNPs (n=9) and their corresponding MAF, OR and UNS
| SNP | Chromosome | Allelic | MAF | Unique Nucleotide | Forward | Quadruplex(n=4) |
|---|---|---|---|---|---|---|
| OR | Sequences (UNS) | Reverse | Quintuplex (n=5) | |||
| rs1016343 | 8 | 1.25 | 0.21 | TTCCCTCCCA | Reverse | 4 |
| TTCCCTCTCA | ||||||
| rs10993994 | 10 | 1.23 | 0.47 | TGACGTCGAA | Forward | 4 |
| TGATGTCGAA | ||||||
| rs16901979 | 8 | 1.44 | 0.18 | ATCTGGCAAA | Forward | 4 |
| CTCTGGCAAA | ||||||
| rs5945619 | X | 1.23 | 0.26 | ACTCCCGCCG | Reverse | 4 |
| ACTCCCGCTG | ||||||
| rs10896449 | 11 | 0.84 | 0.4 | GCTGAAAATT | Reverse | 5 |
| GCTGAAAGTT | ||||||
| rs1859962 | 17 | 1.19 | 0.39 | TGATGAACAC | Forward | 5 |
| GGATGAACAC | ||||||
| rs4242382 | 8 | 1.4 | 0.16 | CCACAGGCCC | Forward | 5 |
| CCGCAGGCCC | ||||||
| rs4430796 | 17 | 0.8 | 0.46 | GATGCTGCAT | Forward | 5 |
| AATGCTGCAT | ||||||
| rs6983267 | 8 | 0.81 | 0.43 | TGAAAGGCAC | Reverse | 5 |
| TGAAAGTCAC |
OR: Odds Ratio, MAF = Minor Allele Frequency
PCR and pyrosequencing primers and primer concentrations for each selected SNP before and after concentration adjustment
| SNP | Quadruplex (n=4) | Multiplex PCR | Multiplex PYRO | |||
|---|---|---|---|---|---|---|
| Quintuplex (n=5) | Conc.( | |||||
| Primer | Initial | Adjusted | Primer | Conc.( | ||
| rs1016343 | 4 | F: 5’-Biot-TCAGGGCAATTACGGAATAACA-3’ | 0.1 | 0.1 | 5’-TGAAGCTGTGAGTAATCA-3’ | 0.4 |
| R: 5’-AATCTAAAGAATGGGGGTCAGAG-3’ | 0.1 | 0.1 | ||||
| rs10993994 | 4 | F: 5’-CTCTCCTCCTCTGCTCTTTTAGGT-3’ | 0.1 | 0.1 | 5’-TTGTTATCATTCCCAA-3’ | 0.4 |
| R: 5’- Biot- AGGCAAAGCTGCATCAAACT-3’ | 0.1 | 0.1 | ||||
| rs16901979 | 4 | F: 5’-GTGGGGTCTTTGTTGTGGA-3’ | 0.1 | 0.1 | 5’-AATGATTTAGCATTACTTAT-3’ | 0.4 |
| R: 5’-Biot-TTATGTTCAGAGCGGTTGAATG-3’ | 0.1 | 0.1 | ||||
| rs5945619 | 4 | F: 5’-Biot-CAGGAAGGGGAACATCACACT-3’ | 0.1 | 0.05 | 5’-CTTGCGGGAGTCTCA-3’ | 0.4 |
| R: 5’- ACGGCTACTATGAGATGAGGAAAC-3’ | 0.1 | 0.05 | ||||
| rs10896449 | 5 | F: 5’-Biot-GGGCCACAGGGAACAA-3’ | 0.1 | 0.15 | 5’-TGACATTCCCCTTCTTA-3’ | 0.4 |
| R: 5’-GCCTTTTCAATGAACCCACA-3’ | 0.1 | 0.15 | ||||
| rs1859962 | 5 | F: 5’-AATAAGAGGCTGCAGACTTTTCC-3’ | 0.1 | 0.05 | 5’-AAATCCCTGCCCGTG-3’ | 0.4 |
| R: 5’-Biot-TAGGCATTCCAAAGATGAAGACTC-3’ | 0.1 | 0.05 | ||||
| rs4242382 | 5 | F: 5’-AAAAGAGGTAACCCAGGGAACA-3’ | 0.1 | 0.075 | 5’-TTGTCCCTCTAGTTATCTTC-3’ | 0.4 |
| R: 5’-Biot-GCATAGAGGGACGCTGTCAA-3’ | 0.1 | 0.075 | ||||
| rs4430796 | 5 | F: 5’-ACGTCCCTTCCTCAGCATCTT-3’ | 0.1 | 0.3 | 5’-GGCAGCACAGACTGGA-3’ | 0.4 |
| R: 5’-Biot-TGTTCCTGACATGAAGCAACTCT-3’ | 0.1 | 0.3 | ||||
| rs6983267 | 5 | F: 5’-Biot-TCTTCCTATCTCAGCTCCCTATCC-3’ | 0.1 | 0.1 | 5’-AATTCTTTGTACTTTTCTCA-3’ | 0.4 |
| R: 5’-GTTGGCTGGCACTGTCTGT-3’ | 0.1 | 0.1 | ||||
aFor each SNP, the concentrations of PCR primers were adjusted in order to select the best conditions for balancing the respective contribution of each SNP in multiplex pyro-signals
Fig. 1pyro-signals generated by each rs1016343 homozygous (CC and TT) and heterozygous (CT) variants
Individual genotype (n=10) for selected SNPs (n=9)
| Patient | rs1016343 | rs10993994 | rs16901979 | rs5945619 | rs10896449 | rs1859962 | rs4242382 | rs4430796 | rs6983267 |
|---|---|---|---|---|---|---|---|---|---|
| 1 | C/C | T/T | C/C | T | G/G | G/G | G/G | A/A | G/T |
| 2 | C/C | C/C | C/C | T | A/G | T/T | G/G | A/A | G/T |
| 3 | C/C | C/C | C/C | C | A/G | T/T | G/G | G/G | G/T |
| 4 | C/C | C/C | C/C | T | A/G | T/G | G/G | A/A | G/G |
| 5 | C/C | C/T | C/C | T | G/G | T/T | G/G | G/A | T/T |
| 6 | T/T | C/T | C/C | T | A/G | T/T | G/G | G/A | T/T |
| 7 | C/C | C/T | C/C | T | A/G | T/G | G/G | G/A | G/G |
| 8 | C/T | C/T | A/A | T | A/A | T/T | G/G | A/A | G/T |
| 9 | C/C | C/C | C/C | C | G/G | T/T | A/G | G/A | T/T |
| 10 | C/C | C/C | C/C | T | A/G | G/G | G/G | G/A | G/T |
Fig. 2Picture of electrophoresis gel of amplification products obtained with 3 DNA samples and 1 negative control, for the quintuplex (samples 1-4) and quadruplex (samples 5-8) PCR, respectively
Quadruplex (n=4) pyro-signals (n=10): results of AdvISER-MH-PYRO after adjustement of primer concentrations
| Patient | rs1016343 | rs10993994 | rs16901979 | rs5945619 | R | ||||
|---|---|---|---|---|---|---|---|---|---|
| Genotype | Contribution | Genotype | Contribution | Genotype | Contribution | Genototype | Contribution | ||
| 1 | C/C | 4.36 (18.6) | T/T | 2.87 (12.2) | C/C | 11.35 (48.4) | T | 4.85 (20.7) | 0.999 |
| 2 | C/C | 5.52 (20.5) | C/C | 7.05 (26.2) | C/C | 10.71 (39.8) | T | 3.66 (13.6) | 0.998 |
| 3 | C/C | 4.58 (19.6) | C/C | 3.66 (15.6) | C/C | 11.09 (47.4) | C | 4.09 (17.5) | 0.999 |
| 4 | C/C | 2.85 (16.4) | C/C | 2.23 (12.8) | C/C | 9.78 (56.1) | T | 2.57 (14.7) | 0.999 |
| 5 | C/C | 4.97 (18.8) | C/T | 5.34 (20.2) | C/C | 10.63 (40.3) | T | 5.44 (20.6) | 0.999 |
| 6 | T/T | 3.92 (16.3) | C/T | 4.93 (20.5) | C/C | 10.2 (42.5) | T | 4.95 (20.6) | >0.999 |
| 7 | C/C | 3.98 (17.9) | C/T | 3.87 (17.4) | C/C | 10.23 (45.9) | T | 4.2 (18.9) | 0.997 |
| 8 | C/T | 4.87 (18.3) | C/T | 5.19 (19.5) | A/A | 12.41 (46.6) | T | 4.18 (15.7) | 0.999 |
| 9 | C/C | 3.05 (18.4) | C/C | 1.82 (11.0) | C/C | 9.18 (55.3) | C | 2.56 (15.4) | 0.999 |
| 10 | C/C | 2.72 (16.2) | C/C | 2.35 (14.0) | C/C | 9.29 (55.2) | T | 2.46 (14.6) | >0.999 |
| Average | 18.1 | 16.9 | 47.7 | 17.2 | |||||
For each patient, the genotype and its absolute and relative contributions to the global signal are computed by AdvISER-MH-PYRO for each SNP, R: confidence index traducing the correlation between the observed multiplex pyro-signal and the sparse regression model constructed by AdvISER-MH-PYRO
Quintuplex (n=5) pyro-signals (n=10): results of AdvISER-MH-PYRO after adjustement of primer concentrations
| Patient | rs10896449 | rs1859962 | rs4242382 | rs4430796 | rs6983267 | R | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | Contriution | Genotype | Contribution | Genotype | Contribution | Genotype | Contribution | Genotype | Contribution | ||
| 1 | G/G | 5.51 (19.4) | G/G | 8.79 (30.9) | G/G | 5.75 (20.2) | A/A | 3.24 (11.4) | G/T | 5.13 (18.1) | 0.998 |
| 2 | A/G | 5.82 (23.2) | T/T | 4.05 (16.1) | G/G | 6.91 (27.5) | A/A | 2.33 (9.3) | G/T | 6.00 (23.9) | 0.998 |
| 3 | A/G | 5.67 (21.0) | T/T | 3.96 (14.7) | G/G | 7.63 (28.3) | G/G | 3.31 (12.3) | G/T | 6.40 (23.7) | 0.999 |
| 4 | A/G | 5.07 (20.6) | T/G | 3.50 (14.2) | G/G | 6.44 (26.1) | A/A | 3.30 (13.4) | G/G | 6.36 (25.8) | 0.996 |
| 5 | G/G | 5.55 (19.3) | T/T | 3.52 (12.2) | G/G | 7.74 (26.9) | G/A | 3.14 (10.9) | T/T | 8.86 (30.8) | 0.999 |
| 6 | A/G | 7.28 (22.4) | T/T | 4.91 (15.1) | G/G | 7.47 (23.0) | G/A | 5.21 (16.0) | T/T | 7.64 (23.5) | 0.998 |
| 7 | A/G | 6.35 (21.1) | T/G | 4.28 (14.2) | G/G | 8.22 (27.3) | G/A | 4.28 (14.2) | G/G | 7.00 (23.2) | 0.996 |
| 8 | A/A | 0.94 (10.7) | T/T | 1.47 (16.7) | G/G | 2.82 (32.1) | A/A | 1.57 (17.9) | G/T | 1.99 (22.6) | 0.998 |
| 9 | G/G | 4.73 (18.6) | T/T | 4.43 (17.4) | A/G | 6.80 (26.8) | G/A | 2.17 (8.5) | T/T | 7.27 (28.6) | 0.997 |
| 10 | A/G | 4.23 (14.5) | G/G | 3.07 (14.5) | G/G | 6.15 (29.1) | G/A | 2.50 (11.8) | G/T | 5.16 (24.4) | 0.999 |
| Average | (19.3) | (16.6) | (26.7) | (12.6) | (24.4) | ||||||
For each patient, the genotype and its absolute and relative contributions to the global signal are computed by AdvISER-MH-PYRO for each SNP, R: confidence index traducing the correlation between the observed multiplex pyro-signal and the sparse regression model constructed by AdvISER-MH-PYRO
Fig. 3Example of a quadruplex (left) and quintuplex (right) pyro-signal identification with AdvISER-MH-PYRO.The multiplex pyro-signal generated by the pyrosequencing machine is displayed before (top) and after (bottom) the analysis. In both cases, it is represented by vertical black lines. After analysis, the contribution of each atom (i.e., each uniplex pyro-signal within the dictionary) is represented by colored boxes stacked on top of the other
Analytical reagent costs (US $)
| Uniplex (n=9) | Quadruplex (n=1) | |
|---|---|---|
| +Quintuplex (n=1) | ||
| DNA extraction | ∼16.5 | ∼16.5 |
| PCR | ∼71.0 | ∼16.0 |
| Pyrosequencing | ∼141.5 | ∼31.5 |
| TOTAL |
| ∼64.0 |
Waste material produced for a full 96-well plate
| Uniplex (n=9) | Quadruplex (n=1) | |
|---|---|---|
| + Quintuplex (n=1) | ||
| PCR plates (n) | 9 | 2 |
| Pipette tips - PCR (n) | 936 | 222 |
| Pyrosequencing plates (n) | 9 | 2 |
| Pipette tips - pyrosequencing (n) | 918 | 211 |
| Bottles pyrosequencing reagents (enzyme+substrate) (n) | 18 | 4 |